Epclusa
Drug
Gilead Sciences Inc
Total Payments
$49.4M
Transactions
52,044
Doctors
15,323
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.5M | 5,808 | 3,280 |
| 2023 | $4.0M | 7,841 | 3,759 |
| 2022 | $4.1M | 6,706 | 2,947 |
| 2021 | $4.5M | 4,400 | 1,929 |
| 2020 | $5.1M | 3,770 | 833 |
| 2019 | $10.7M | 6,964 | 2,169 |
| 2018 | $9.6M | 7,810 | 2,572 |
| 2017 | $6.8M | 8,745 | 3,657 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.1M | 980 | 42.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20.9M | 10,122 | 42.3% |
| Travel and Lodging | $3.3M | 9,298 | 6.6% |
| Food and Beverage | $2.5M | 31,007 | 5.1% |
| Consulting Fee | $1.6M | 559 | 3.3% |
| Space rental or facility fees (teaching hospital only) | $4,750 | 2 | 0.0% |
| Education | $986.67 | 76 | 0.0% |
Payments by Type
General
$28.3M
51,064 transactions
Research
$21.1M
980 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection | Gilead Sciences, Inc. | $2.3M | 0 |
| Community Access, Retention in Care, and Education for Hepatitis C (CARE-C) | Gilead Sciences, Inc. | $1.9M | 0 |
| Universal Hepatitis C Screening and Linkage with Therapy | Gilead Sciences, Inc. | $1.8M | 0 |
| Towards Elimination of Hepatitis C in California: Building a PCP Network of HCV Champions | Gilead Sciences, Inc. | $1.6M | 0 |
| Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus during Pregnancy (STORC) | Gilead Sciences, Inc. | $1.5M | 0 |
| City Wide Hepatitis C Screening and Linkage to Care | Gilead Sciences, Inc. | $1.4M | 0 |
| The No One Waits (NOW) Study: Acceptability, feasibility, and effectiveness of a community based on-site point-of-diagnosis HCV treatment study | Gilead Sciences, Inc. | $1.1M | 0 |
| A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations who are HCV Treatment Naive with Evidence of Active HCV Infection: The MINMON Study | Gilead Sciences, Inc. | $783,900 | 0 |
| Enhancing HCV Screening, Access, and Linkage to Care in the Homeless Population | Gilead Sciences, Inc. | $776,871 | 0 |
| A randomized study of a rapid HCV treatment initiation strategy (HCV Seek, Test and Rapid Treatment - HCV ST&RT) compared to standard care in young PWID | Gilead Sciences, Inc. | $674,348 | 0 |
| A Phase 1 Study of Velpatasvir/Sofosbuvir for Pregnant Women with Chronic Hepatitis C Virus Infection | Gilead Sciences, Inc. | $613,952 | 0 |
| A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection | Gilead Sciences Inc | $575,651 | 0 |
| Towards Elimination of Hepatitis C in California: Building a PCP Network of HCV Champions | Gilead Sciences Inc | $564,784 | 0 |
| Decreasing recidivism through HCV testing, linkage to care and treatment. The Decrease-C Study. A joint Denver Health and Denver Adult Probation collaboration. | Gilead Sciences, Inc. | $534,247 | 0 |
| PRO-ACT: Prevention of De Novo HCV with Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant | Gilead Sciences, Inc. | $401,583 | 0 |
| An evaluation of vertical transmission of hepatitis C virus (HCV) and natural history of chronic HCV in pregnant women with subsequent sofosbuvir/velpatasvir treatment post-partum. | Gilead Sciences, Inc. | $372,775 | 0 |
| HCV Testing and Linkage to Care for Persons on Probation or Parole | Gilead Sciences, Inc. | $363,850 | 0 |
| A Novel Approach Continuum to Identification to Elimination in HCV-Infected Individuals on Opioid Substitution Therapy | Gilead Sciences, Inc. | $350,235 | 0 |
| A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir and Ribavirin in Subjects with Chronic HCV Infection and Child-Pugh Turcotte C Cirrhosis | Gilead Sciences Inc | $338,500 | 0 |
| HCV Seroprevalence in Pregnant Patients in Two NYC Hospitals | Gilead Sciences, Inc. | $326,411 | 0 |
Top Doctors Receiving Payments for Epclusa
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Raj Kumar | — | Gilbert, AZ | $21.1M | 1,034 |
| , M.D | Internal Medicine | Buffalo, NY | $357,230 | 275 |
| , MD | Transplant Surgery | Los Angeles, CA | $328,506 | 264 |
| , M.D | Gastroenterology | La Jolla, CA | $324,138 | 289 |
| , M.D | Hepatology | Fort Worth, TX | $314,838 | 251 |
| , MD | Infectious Disease | San Diego, CA | $311,492 | 327 |
| , M.D | Gastroenterology | Detroit, MI | $289,414 | 231 |
| , MD | Internal Medicine | Atlanta, GA | $289,387 | 318 |
| , M.D | Hepatology | Baton Rouge, LA | $265,753 | 215 |
| , MD | Gastroenterology | Seattle, WA | $255,869 | 204 |
| , M.D | Internal Medicine | Kansas City, KS | $254,198 | 161 |
| Imtiaz Alam | — | Austin, TX | $246,080 | 198 |
| , MD | Gastroenterology | Atlanta, GA | $239,964 | 191 |
| , M.D | Gastroenterology | Tamarac, FL | $227,574 | 213 |
| , D.O | Internal Medicine | Mobile, AL | $226,679 | 160 |
| , MD | Gastroenterology | Mobile, AL | $219,213 | 192 |
| , DO | Gastroenterology | Allentown, PA | $202,884 | 194 |
| , M.D | Gastroenterology | San Antonio, TX | $198,406 | 164 |
| , MD | Hepatology | New York, NY | $191,430 | 156 |
| , CRNP | Family | Pittsburgh, PA | $188,950 | 460 |
| , M.D | Gastroenterology | Rollingwood, TX | $179,646 | 168 |
| , MD | Gastroenterology | Chicago, IL | $173,040 | 154 |
| , MD | Gastroenterology | Columbus, OH | $173,040 | 173 |
| , M.D | Gastroenterology | Detroit, MI | $169,298 | 136 |
| , MD | Hepatology | New York, NY | $165,995 | 126 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $42.6M
- Gilead Sciences Inc $6.8M
Product Information
- Type Drug
- Total Payments $49.4M
- Total Doctors 15,323
- Transactions 52,044
About Epclusa
Epclusa is a drug associated with $49.4M in payments to 15,323 healthcare providers, recorded across 52,044 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $4.5M was paid across 5,808 transactions to 3,280 doctors.
The most common payment nature for Epclusa is "Unspecified" ($21.1M, 42.7% of total).
Epclusa is associated with 20 research studies, including "A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection" ($2.3M).